Biomark Diagnostics Inc

FRA:20B (Canada)  
€ 0.18 (-9.5%) Apr 25
At Loss
Market Cap:
€ 18.90M ($ 20.25M)
Enterprise V:
€ 19.42M ($ 20.81M)
Volume:
-
Avg Vol (2M):
700.00
Also Trade In:

Business Description

Description
Biomark Diagnostics Inc is a Canada-based oncology-focused company. It is engaged in the development of the early-stage cancer diagnostic technology platform. The company develops non-invasive cancer diagnostic solutions which will help to detect, monitor, and assess early treatment for cancer. Its research and development are focused on the role that metabolomics plays in early cancer detection. It is currently focused on bringing its liquid biopsy-based cancer diagnostic tests and detection solution to commercialization.
Name Current Vs Industry Vs History
Cash-To-Debt 0.29
Equity-to-Asset -0.42
Debt-to-Equity -1.94
Debt-to-EBITDA -1.03
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -9.27
Distress
Grey
Safe
Beneish M-Score -3.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 49.69
9-Day RSI 49.85
14-Day RSI 49.84
6-1 Month Momentum % 7.02
12-1 Month Momentum % 24.49

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.28
Quick Ratio 0.28
Cash Ratio 0.23
Days Sales Outstanding 69.88

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.8
Shareholder Yield % 0.71
Name Current Vs Industry Vs History
Operating Margin % -999.39
Net Margin % -937.81
FCF Margin % -572.57
ROA % -177.97
ROIC % -139.8
ROC (Joel Greenblatt) % -232.09

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 300
EV-to-EBIT -19.7
EV-to-EBITDA -27.15
EV-to-Revenue 173.57
EV-to-FCF -29.73
Earnings Yield (Greenblatt) % -5.07
FCF Yield % -3.41

Financials

FRA:20B's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Biomark Diagnostics Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 0.113
EPS (TTM) (€) -0.042
Beta -1.07
Volatility % 72.94
14-Day RSI 49.84
14-Day ATR (€) 0.008022
20-Day SMA (€) 0.1821
12-1 Month Momentum % 24.49
52-Week Range (€) 0.105 - 0.248
Shares Outstanding (Mil) 90.89

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Biomark Diagnostics Inc Filings

Filing Date Document Date Form
No Filing Data

Biomark Diagnostics Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Biomark Diagnostics Inc Frequently Asked Questions

What is Biomark Diagnostics Inc(FRA:20B)'s stock price today?
The current price of FRA:20B is €0.18. The 52 week high of FRA:20B is €0.25 and 52 week low is €0.11.
When is next earnings date of Biomark Diagnostics Inc(FRA:20B)?
The next earnings date of Biomark Diagnostics Inc(FRA:20B) is .
Does Biomark Diagnostics Inc(FRA:20B) pay dividends? If so, how much?
Biomark Diagnostics Inc(FRA:20B) does not pay dividend.

Press Release

Subject Date
No Press Release